The widespread progression of malignant cells on peritoneal surfaces results in copious fluid production. Neoadjuvant systemic chemotherapy was thought appropriate for biphasic or sarcomatoid malignant peritoneal mesothelioma. Median survival of diffuse malignant peritoneal mesothelioma using traditional treatment modalities (combined pleural and peritoneal mesothelioma*). Malignant peritoneal mesothelioma (MPM) is a rare condition with an overall incidence of one to two cases per million.
Malignant peritoneal mesothelioma symptoms may not appear until 20 to 30 years after the first exposure to asbestos. Most peritoneal mesothelioma diagnoses are made when the malignancy is in an advantage stage and diagnosis, alone, takes on average four months. Primary malignant peritoneal mesothelioma is a are disease, accounting for only about 10% of all mesotheliomas. Malignant peritoneal mesothelioma is a rare type of cancer that occurs in the thin cell walls which surround the abdominal cavity, known as the peritoneum and is caused by asbestos. Peritoneal mesothelioma is known only to be caused by exposure to asbestos, a microscopic natural fiber that was used heavily in industry. Patients of peritoneal mesothelioma may be eligible for financial compensation if they exposed to asbestos.
